Tag Archives: NXTM

Hot Blue Chip Stocks To Watch For 2019

General Electric was blasted on Wednesday by workers, retirees and shareholders bemoaning the downfall of the company they love.

At its annual meeting, GE (GE) got an earful from employees and investors who pleaded with management to right the ship after a disastrous year.

“I believe it was arrogance and a series of bad business decisions,” former employee Bill Freeda said. “Our board of directors clearly has been AWOL.”

Another shareholder said: “GE, which was once one of the preeminent companies in the world — the bluest of blue chips — is now an embarrassment.”

The past 12 months has been one of the darkest periods in GE’s 126-year history. A cash crisis, brought on by years of bad deal-making, forced GE to cut its dividend in half and lay off thousands of workers. GE’s stock price has crashed by 50%, and calls to kick it out of the Dow have grown louder.

Despite the deep criticism of past and current GE leaders, the company’s nominees to the board were all elected on Wednesday. None of the shareholder proposals calling for reform were adopted, though one pushing for splitting the CEO and chairman roles received strong support.

Hot Blue Chip Stocks To Watch For 2019: Mesabi Trust(MSB)

Advisors’ Opinion:

  • [By Dan Caplinger]

    The past year has been a good one for stocks, but only the best dividend stocks have been able to deliver gains of 50% or more while still sporting at least a 4% yield. Still, a handful of stocks have made the cut. Below, we’ll look more closely at Mesabi Trust (NYSE:MSB), Macy’s (NYSE:M), and Seagate Technology (NASDAQ:STX) to see how they accomplished this impressive feat and whether they still have further gains in store for new investors.

Hot Blue Chip Stocks To Watch For 2019: NxStage Medical, Inc.(NXTM)

Advisors’ Opinion:

  • [By Max Byerly]

    NxStage Medical (NASDAQ:NXTM) and IRIDEX (NASDAQ:IRIX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

  • [By Dan Caplinger]

    For nine months now, investors in NxStage Medical (NASDAQ:NXTM) have looked forward to the future. Having received and accepted a bid from Fresenius Medical Care (NYSE:FMS) last August to purchase the company for $30 per share in cash, NxStage has seen a lot more volatility in its stock than most acquisition targets. With a key deadline approaching within the next three months, it’s hard not to be anxious about whether the deal will actually go through.

  • [By Max Byerly]

    NxStage Medical, Inc. (NASDAQ:NXTM) reached a new 52-week high on Monday . The stock traded as high as $29.32 and last traded at $29.20, with a volume of 8721 shares traded. The stock had previously closed at $29.15.

  • [By Dan Caplinger]

    It’s been more than a year since NxStage Medical (NASDAQ:NXTM) accepted an acquisition bid from Fresenius Medical Care (NYSE:FMS). Investors have looked forward to the $30 per share in cash that Fresenius offered, but there’ve been countless delays in the process that everyone had hoped would be over by now. Indeed, with an Aug. 7 deadline under the terms of the deal, some investors had started to get more nervous about whether the acquisition would happen at all.

  • [By Max Byerly]

    ValuEngine downgraded shares of NxStage Medical (NASDAQ:NXTM) from a buy rating to a hold rating in a research note published on Thursday morning.

    NXTM has been the topic of several other research reports. BidaskClub raised NxStage Medical from a strong sell rating to a sell rating in a research note on Saturday, March 24th. Zacks Investment Research lowered NxStage Medical from a hold rating to a strong sell rating in a research note on Tuesday, May 15th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $30.50.

  • [By Stephan Byrd]

    NxStage Medical (NASDAQ:NXTM) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Friday.

Hot Blue Chip Stocks To Watch For 2019: Community Trust Bancorp, Inc.(CTBI)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Community Trust Bancorp, Inc. (NASDAQ:CTBI) reached a new 52-week high and low on Wednesday . The stock traded as low as $52.30 and last traded at $52.10, with a volume of 1141 shares trading hands. The stock had previously closed at $52.05.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Community Trust Bancorp (CTBI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Community Trust Bancorp (CTBI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Community Trust Bancorp (CTBI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Blue Chip Stocks To Watch For 2019: Truett-Hurst, Inc.(THST)

Advisors’ Opinion:

  • [By Max Byerly]

    Press coverage about Truett-Hurst (NASDAQ:THST) has trended somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Truett-Hurst earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.6772286424113 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

  • [By Joseph Griffin]

    Media coverage about Truett-Hurst (NASDAQ:THST) has been trending somewhat positive this week, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Truett-Hurst earned a daily sentiment score of 0.00 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 44.6844029134937 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

  • [By Logan Wallace]

    Media coverage about Truett-Hurst (NASDAQ:THST) has trended somewhat positive on Tuesday, Accern Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Truett-Hurst earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.6772286424113 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Hot Blue Chip Stocks To Watch For 2019: Duff & Phelps Utilities Income, Inc.(DNP)

Advisors’ Opinion:

  • [By Shane Hupp]

    Stratos Wealth Partners LTD. lifted its holdings in DNP Select Income Fund Inc. Common Stock (NYSE:DNP) by 108.1% during the first quarter, Holdings Channel reports. The institutional investor owned 17,485 shares of the investment management company’s stock after purchasing an additional 9,084 shares during the period. Stratos Wealth Partners LTD.’s holdings in DNP Select Income Fund Inc. Common Stock were worth $180,000 as of its most recent filing with the SEC.

SA Interview: Event-Driven Investing With Donostia

Donostia is an analyst at an event-driven hedge fund who focuses on long/short ideas across the capital structure. We emailed with Donostia about how regulators have changed their definition of competition as part of antitrust review, how merger arb returns should be measured, and whether the type of buyer impacts the likelihood of deal closing.

Seeking Alpha: Can you walk us through your investment decision making process for merger arb and event-driven ideas, from how you source them to execution?

Donostia: For the merger arb strategy, I focus mainly on announced deals, so it is relatively straightforward in terms of sourcing. There usually isnt a rush to set an arb spread or position on the day of announcement of course, there are exceptions (competitive process, long telegraphed deal where potential regulatory issues/approvals known), but more often than not, you would prefer to see the contract (usually takes a day or two) and wait for the official handover from long-only/fundamental investors or short sellers covering (i.e. thereby driving spread tighter than it would be). In the interim, we are trying to understand why there is a spread and what risks we are underwriting (i.e. MOFCOM/China approvals, anti-trust, buyer vote, weak contract/buyer). You should have a good idea of what risks are contributing to the spread and then can compare it to the rest of the available universe. For example, currently, all deals with MOFCOM approval pending are trading at elevated spreads (MSCC/MCHP, CAVM/MRVL, NXPI/QCOM, ORBK/KLAC, OCLR/LITE, COL/UTX) the risk/reward for each of these MOFCOM sensitive names differs, and you would be better suited by being larger in a name which presents the most attractive risk/reward. Pretty simple for the most part.

SA: How important is it to do fundamental analysis on the acquirer and target? Your thesis on NxStage Medical (NASDAQ:NXTM) is a case in point.

D: Fundamental analysis is critical in the process, especially for the longer duration deals where a thorough anti-trust review is expected. Since you wont be getting much guidance from management, and there will unlikely be conference calls, a lot of the valuation will fall upon relative value metrics. As such, its important to have a good feel for any peers and the sector overall. I think the ongoing situation with NXPI has highlighted that reliance on just peer comps was wrong without having some sense with where you were in the overall cycle for the Semi space.

I think NXTM is definitely a case where you need to rely on fundamental analysis; not only for assessing the market-implied probability but also in the event the deal breaks, and you are left holding a company which hasnt been run as a standalone company for a while. I think often that reality contributes to the current deal spread. For example, would you want to own AKRX (chance of bankruptcy and term loan trading below par) or Time Warner (NYSE:TWX) (fundamentals plugging along but a high-quality name with chance of other potential buyers)?

In the case of NXTM, we are focused on the Home-Hemodialysis (HHD) market in which NXTM is the major player. We arrived at our break price of $19 vs. the unaffected (day before deal announcement price) of $23-24 after spending some more time on industry dynamics. Our conclusion was that the HHD market would likely face additional pressure as there was no guarantee that NXTM would be able to maintain their >95% market share. As such, we felt a sum of the parts analysis which incorporated some decline in the NXTM HD and PD business.

Given its dominance in the HHD market, we thought it was appropriate to apply a 3x multiple on revenues despite the potential headwinds as this would also incorporate a potential boost from the approval of NXTMs PD machine. Based on potential market penetration and the gradual shift towards PD overall, sell-side analysts believe that the PD segment alone could represent $5-8/share in value.

SA: How do you determine how long until a deal closes? What factors can delay this process? If a deal is delayed, do you exit or continue to hold?

D: When a deal is announced, the acquirer will normally provide details on needed approvals and closing guidance. Common regulatory approvals required are HSR/US Antitrust, FTC, FCC, EC, MOFCOM, CFIUS, State PUCs. There are plenty of precedents here, and you can have a good initial estimate of timing for each approval based on when filings are submitted and how thorough of a review you might expect. If it is a horizontal merger between two US companies that would result in total competition decreased from 4 to 3 companies (ex. S/TMUS), then you would likely expect a long review given the clear competition issues.

A new wrinkle has been that in addition to horizontal mergers, vertical mergers are also receiving extra scrutiny. This has resulted in longer 2nd Requests which are on average 4-6 months. In these instances, regulatory bodies are often looking for structural vs. behavioral remedies this often entails finding a buyer for assets/business segments to be divested which will add to the timeline as the DOJ/FTC often will have to vet a buyer before signing off.

Another example of delays weve seen a fair amount this year has to do with CFIUS and MOFCOM. In the case of CFIUS, weve seen a number pull at refiles this is when an acquirer realizes it will not get CFIUS approval after the initial 30-day review and subsequent 45-day follow-on review. Rather than letting the clock run out, the buyer will pull its application after some consultation with CFIUS and refile after incorporating some feedback. Naturally, this usually creates some volatility in the spread or target stock as two or more pull and refiles usually signal that something is wrong with the buyer/remedies.

This year at least, delays in deals have become the norm. Many arbs have found their closing estimates far too aggressive, and we are now seeing elevated spreads reflecting this (i.e. wider gross spreads to account for diminished IRRs). Given the leverage employed in this strategy, cost of capital should be deducted from the IRR to get a more accurate view. Alternatively, viewing the IRR as a spread above a risk-free benchmark (usually some term of LIBOR in line with estimated deal duration) is a better way of viewing risk/reward across the investable universe in merger arb.

Deciding to add or reduce because of a delay comes down to the nature of the delay not trying to sound pedantic, but an unexpected pull and refile (ex. SNI/DISCA) can sometimes provide a great buying opportunity. I wish it were more precise. But a clear example of this is the TWX/T or the AKRX/FRE which both went through/are about to go through litigation. Sometimes, it’s better to reduce and reassess as more details come out in the case of AKRX, it was key to see both the complaint and rebuttal before adding or reducing the position size.

SA: Can you discuss where and how regulators have changed their definition of competition as part of antitrust review? Are there any industries (or companies) that effectively cannot consolidate for various reasons?

D: As mentioned in the prior question, there is now extra scrutiny for vertical mergers – a relatively new development. Normally, regulators are more concerned with horizontal mergers (i.e. buying a competitor or peer in the same industry). This has made things pretty difficult for many arbs, to say the least. As such, now, any deal with a potential vertical component will likely face a 2nd Request/extended review moreover, they will likely require a structural remedy, usually in the form of a divestiture. As long as Delrahim at the DoJ holds the position, we can assume that Vertical Mergers will be guaranteed a close review.

SA: How should merger arb returns be measured? Are there any downsides to using IRR?

D: Given this is supposed to be a market neutral strategy with low volatility hard to believe, given the action of late! – merger arb returns should be measured based on risk-adjusted returns. I think you also need to look at how a merger arb portfolio is structured. This really isnt a measure of returns, but looking at hit rates and max drawdowns for broken deals also provides some insight into how a manager thinks about risk/reward. Given that the downside for many deals is in the 20-30% range, a manager can only stomach so many broken deals without requiring more risk on other deals to get back to even. Avoiding the landmines (and thus, being able to change your mind when the information changes) can be a crucial skill in merger arb.

SA: Does the type of buyer (strategic vs. financial) impact the likelihood of the deal closing?

D: Again, it will depend on how the contract is structured. Large strategic buyers who are repeat buyers do provide some comfort, but as we saw in ALR/ABT, sometimes, a CEO doesnt care about his reputation if he wants to get out of a deal.

I think with rates rising and leverage set to become an issue in the near year or so, you have to look at LBOs/Private Equity buyers with a bit more scrutiny. You want to know if the target is in an industry that is their core competency, how big of an equity check they are writing, how big the equity check is relative to a reverse termination fee (if any). To the best of your ability, try to put yourself in the shoes of the buyer: How big will the target be relative to the AUM? Does the target fit with any portfolio companies? Do some of the managing partners have operational experience in the space? Usually, these types of questions are more pertinent to smaller and mid-sized LBOs vs. Mega-Fund LBOs. A good example of this recently was Siris Capital and their offer to buy SNCR. Siris made a tentative offer to buy SNCR for ~$18 after building up a ~6% stake in the open market following SNCRs CFO and CEO leaving after only 3 months and a 50% decline in SNCRs price. Learning a bit more about Siris from publicly available information, one could deduce that they really were interested in SNCR just for Intralinks (a recently completed acquisition by SNCR). After due diligence, Siris became aware of some material issues in SNCRs core business. Without delving too much into the minutiae, Siris decided against buying SNCR whole for Intralinks. Instead, Siris opted to structure two separate deals:

The purchase of Intralinks outright for a cash consideration A private placement to recapitalize the SNCR RemainCo

Private equity buyers will usually try to find a way out, restructure or angle for a price cut if things go belly up. This isnt to say that other buyers wont have buyers remorse (ex. AKRX and Fresenius). But understanding the language in the contract is critical particularly concerning regulatory efforts (Hell or High-Water, Reasonable Best Efforts etc.) and reverse termination fees and under what circumstances the fee would need to be paid to the target company. Sometimes, private equity buyers can be a bit strategic with end dates and termination dates they have negotiated in the contract.

SA: What traits do you look for in a pre-event name? Are there any that stand out now as examples?

D: I try to avoid pre-event names, to be honest. There are times when the downside or risk/reward are attractive, and its a company you would want to own otherwise in a sector that has some strong characteristics. I think also vetting the source of the rumor for a buyout is also helpful. A source from the Wall Street Journal or Bloomberg carries a bit more weight than from some of the other publications catering to the Merger Arbitrage/Event-Driven community.

LADR was an example of a pre-event name we were comfortable holding, given that it is set up well for rising rates, was trading below adjusted book value, and was run by a stellar management team. LADR was trading in the mid-$14 at a discount to its book value and with a >8% dividend yield that was well covered. The stock traded to $15+ when Related Fund Management announced they had offered to take LADR private.

We had been familiar with LADR previously and were comfortably underwriting their Core REIT business, which we viewed as stable and with minimal expected volatility with regards to earnings. The issue with LADR had long been that its conduit/securitization business was lumpy (albeit extremely profitable) and thus made it hard for most institutional investors to get comfortable with the business model. Essentially, investors cant decide if LADR is a traditional mortgage REIT or something else. LADR CEO Brian Harris summed it up nicely on the last earnings call:

We spend a lot of time meeting people and investors that run with first and last names and we tell our story to them and we give them the value proposition about internally managed company with a lot of internal ownership. We’ve never raised secondary capital. We’ve got an ironclad balance sheet, and we go through all the checkmarks that we do to run a safe company. But deep down inside, I do believe, half of this market is driven by three factors, market cap, dividend and average daily volume. And I don’t think that those algorithms that make those purchases, no if you own subordinate debt or senior secured, they don’t know if you’re internally or externally managed. And I think that they pay attention to rising interest price to book value, and I think they pay attention to dividend increases on a regular basis.

But I think we’ve we’ve been walking around here at Ladder, questioning, how do we make something happen? And finally, you just have to sit down and realize, we’re REIT, and REITs are perceived to be an out of favor asset class, when rates are perceived to be rising. There are plenty of REITs that do very well, while interest rates rise. And that is a fact that I think everybody on this call knows. But I don’t think a lot of those algorithms take that into account. And you will see sometimes where, the bond market is available at 6%, but a REIT might raise money at a dividend rate much higher than that. So why would they do that? That’s typically an externally managed REIT, that’s in the assets under management model.

But I don’t think that that the algorithms are picking that up. So, I think as I said last year, we went to great pains to set up our balance sheet and our asset liability set to make sure that we could really optimize our earnings power. We’ve got the right product mix. I think the analysts and our investors do understand that, and I think we’re in the self-help model now, because I don’t think we can wait any more to reward our shareholders. I don’t think we can wait for the efficient market theory, because if the Fed says they’re going to raise rates four times, REITs are going to go down. Now I understand why residential mortgage REITs go down. I don’t understand why mortgage servicer would go down, nor do I understand why a REIT with a lot of exposure to LIBOR assets goes down, but down they go.

Well, when Related Fund Management and LADR ended talks of an offer at $15.00, the stock sold off indiscriminately and provided a great opportunity to add to a solid rate sensitive name with a well-covered 9% yield and a management team that owns 12% of the company and is aligned with shareholders. It would have been nice to get an improved offer of say $17 which is still below what we think LADR is worth but we were happy to add to the position on the pullback.

SA: Whats one of your highest conviction ideas right now?

D: Well, clearly LADR in the pre-event/special situations space. Among the announced deals I am positive on some of the smaller names such as CAFD/Capital Dynamics and NXTM/Fresenius. I am also positive on AKRX/Fresenius, but you need to size that one conservatively, given the downside is hard to gauge I am using around $6-7 for a break price, but there are some who think $0 cant be ruled out.

The current gross spread on AKRX is ~160% with AKRX at $13.05 vs. an offer of $34.00. AKRX has already filed a complaint in Delaware Court to enforce the contract and force Fresenius to close the deal. Fresenius has also filed a rebuttal to AKRXs complaint. Both the complaint and rebuttal are chock full of propaganda as you would expect. AKRX is claiming they have met all obligations and that Fresenius is dragging its feet with regards to the regulatory (FTC) approvals. Fresenius is claiming that AKRX has not fulfilled all its representations and warranties (R&Ws), specifically, the following MAC qualified representations and warranties:

Section 3.05 – (p. 107 in DEFM 14A) – Company SEC Documents; Undisclosed Liabilities Section 3.06 – Absence of Certain Changes Section 3.08 – Compliance with Laws; Permits Section 3.18 – Regulatory Compliance (Subsections A through G)

Of these R&Ws, it seems that Section 3.18 is the most pertinent. But the difficulty for Fresenius is that it needs to prove that the breach of these R&Ws alone or in aggregate would amount to a MAC (Material Adverse Change) in the business. I am of the view that Fresenius has not made the case a MAC has occurred and will have difficulty doing so. Fresenius is alleging widespread fraud (Case No. 2018-0300-JTL, Akorn, Inc., v Fresenius Kabi AG, Quercus Acquisition, Inc. and Fresenius SE & Co. KGaA) at AKRX based on the revelation that the VP of Quality Assurance allowed fabricated data from a 2012 ANDA to be resubmitted in response to a CRL from the FDA, which is for a drug AKRX acquired the branded version of in 2013. For Fresenius to get out of this deal, they will need to prove that fraud has to come from the very top (i.e. Management promoting systemic fraud). Given that John Kapoor is associated with AKRX, this is definitely justified. But in reviewing the transcript from the motion to expedite the hearing, Fresenius lawyers were reluctant to admit that 4 or 5 people were mentioned in the disclosure letter as part of the scope of discovery allowed per Section 8.12 of the contract. Given that there were 5 small ANDAs that were allegedly doctored/tampered with, it would be hard to imagine top-level management pushing for knowing fraud again, on such a small ANDA/potential market. If this was Restasis, it would be a different issue, but so far, we have not heard that from Fresenius.

Restasis is a pipeline product for AKRX which has a substantial addressable market. The current progress on an ANDA for Restasis is unclear as AKRX (and other generics) does not normally comment on its pipelines. However, sales for branded Restasis were ~$1.4 billion last year in the US. There are multiple filers for generic Restasis (effectively generic eyedrops/ophthalmic solutions). As for most generic drug manufacturers, getting to market first is crucial – perhaps, Fresenius believes the potential FDA investigations could delay Restasis coming to the market. If this were the case, then you could argue there has been material impairment to the pipeline. But if you were Fresenius, wouldn’t you already be screaming this from a mountain top? or at the very least, alleging that this item was up in the air? I guess we will find out.

I plan on writing an article about the AKRX situation as things develop. There is still a lot going on, but I think it is definitely one of the more interesting merger arb names out there.

***

Thanks to Donostia for the interview. If you’d like to check out or follow their work, you can find the profile here.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: Check with individual articles or authors mentioned for their positions. Donostia is long CAVM, TWX, TMUS, LADR, NXPI, COL, AKRX, NXTM and short MRVL, T, S, UTX.

Best Stocks To Invest In Right Now

1. Trump team heads to Asia: A trade war with China was once unthinkable. Now, that nightmare scenario is sitting atop Wall Street’s worry list.

The fear is that confrontation between the world’s two biggest economies derails trade, destabilizing the global economy.

That’s why it’s an unmistakable positive that President Donald Trump is sending top economic officials to China this week for trade negotiations. Talks are certainly better than tariffs.

The hope is that Team Trump will leave Beijing with the framework for a trade agreement that both sides can live with. Not only would that avoid the escalation that investors fear, but it could put a stop to the unfair trade practices that cost American businesses billions.

“I think we’ve got a very good chance of making a deal,” Trump said last week.

One potential problem: Trump’s team must present a united front. That could be a challenge because the delegation is expected to include a mix of trade hawks and staunch advocates of free trade.

Best Stocks To Invest In Right Now: St. Jude Medical, Inc.(STJ)

Advisors’ Opinion:

  • [By Emily Stewart]

    Paulson picked up 45,500 shares of St. Jude Medical (STJ) . The stake is worth $3.5 million as of the end of the second quarter.

    St. Jude Medical develops, manufactures and distributes cardiovascular medical devices for cardiac rhythm management, cardiovascular, atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain. It has a $23.6 billion market cap and trades at a P/E of 36.03. 

Best Stocks To Invest In Right Now: B. Riley Financial, Inc.(RILY)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of Standard General L.P.’s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Standard+General+L.P.

    These are the top 5 holdings of Standard General L.P.National CineMedia Inc (NCMI) – 12,576,000 shares, 60.53% of the total portfolio. New PositionTime Inc (TIME) – 3,181,424 shares, 29.62% of the total portfolio. Turning Point Brands Inc (TPB) – 305,319 shares, 3.58% of the total portfolio. Shares added by 189.90%CafePress Inc (PRSS) – 2,500,000 shares, 3.12% of the total portfolio. New PositionB. Riley Financial Inc (RILY) – 167,736 shares, 1.97% of the total portfoli

  • [By WWW.GURUFOCUS.COM]

    For the details of Standard General L.P.’s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Standard+General+L.P.

    These are the top 5 holdings of Standard General L.P.National CineMedia Inc (NCMI) – 12,576,000 shares, 60.53% of the total portfolio. New PositionTime Inc (TIME) – 3,181,424 shares, 29.62% of the total portfolio. Turning Point Brands Inc (TPB) – 305,319 shares, 3.58% of the total portfolio. Shares added by 189.90%CafePress Inc (PRSS) – 2,500,000 shares, 3.12% of the total portfolio. New PositionB. Riley Financial Inc (RILY) – 167,736 shares, 1.97% of the total portfoli

  • [By WWW.GURUFOCUS.COM]

    For the details of Standard General L.P.’s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Standard+General+L.P.

    These are the top 5 holdings of Standard General L.P.National CineMedia Inc (NCMI) – 12,576,000 shares, 60.53% of the total portfolio. New PositionTime Inc (TIME) – 3,181,424 shares, 29.62% of the total portfolio. Turning Point Brands Inc (TPB) – 305,319 shares, 3.58% of the total portfolio. Shares added by 189.90%CafePress Inc (PRSS) – 2,500,000 shares, 3.12% of the total portfolio. New PositionB. Riley Financial Inc (RILY) – 167,736 shares, 1.97% of the total portfoli

  • [By ]

    2. B.Riley Financial (Nasdaq: RILY)
    This unusual microcap operating as a FINRA-licensed broker-dealer and an independent investment bank is setting up to be an ideal buying opportunity.

Best Stocks To Invest In Right Now: NxStage Medical, Inc.(NXTM)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Thursday, healthcare shares dipped by 0.51 percent. Meanwhile, top losers in the sector included NxStage Medical, Inc. (NASDAQ: NXTM), down 8 percent, and Valeant Pharmaceuticals Intl Inc (NYSE: VRX), down 9 percent.

Best Stocks To Invest In Right Now: PetroChina Company Limited(PTR)

Advisors’ Opinion:

  • [By Money Morning News Team]

    PetroChina Co. Ltd. (NYSE ADR: PTR) is China’s largest oil company with a market cap of $216.52 billion. PTR is partially owned by the Chinese government.

  • [By Max Byerly]

    ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect PetroChina (PTR) Stock Price” was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3368551/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-petrochina-ptr-stock-price.html.

Hot Small Cap Stocks To Buy For 2018

It was a mixed day for stocks as blue chips managed to squeak out a gain and small-caps got crushed ahead of tomorrow’s Fed announcement.

Keith Bedford for The Wall Street Journal

The S&P 500 fell 0.2% to 2,015.93 today, while the Dow Jones Industrial Average rose 22.40 points, or 0.1%, to 17,251.53. The Nasdaq Composite fell 0.5% to 4,728.67. The Russell 2000 tumbled 1.6% to 1,066.67, the first time since Sept. 2011 that the small-company benchmark fell by at least 1.5% and the Dow Jones Industrial Average finished higher.

The folks at Bespoke Investment Group consider the Russell 2000′s underperformance versus the S&P 500 this year:

Including today, the S&P 500 is down 1.6%, while the Russell 2000 is down 6.1%. Todays underperformance in small caps is just a continuation of what has been an extremely consistent trend of daily underperformance this year.

Hot Small Cap Stocks To Buy For 2018: NxStage Medical, Inc.(NXTM)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Thursday, healthcare shares dipped by 0.51 percent. Meanwhile, top losers in the sector included NxStage Medical, Inc. (NASDAQ: NXTM), down 8 percent, and Valeant Pharmaceuticals Intl Inc (NYSE: VRX), down 9 percent.

Hot Small Cap Stocks To Buy For 2018: Allison Transmission Holdings, Inc.(ALSN)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Allison Transmission (NYSE:ALSN) – Investment analysts at Oppenheimer increased their FY2018 earnings per share (EPS) estimates for Allison Transmission in a research note issued on Monday, April 30th. Oppenheimer analyst I. Zaffino now expects that the auto parts company will post earnings of $3.79 per share for the year, up from their previous forecast of $3.32. Oppenheimer also issued estimates for Allison Transmission’s FY2019 earnings at $4.16 EPS.

  • [By Joseph Griffin]

    ARP Americas LP lowered its stake in shares of Allison Transmission (NYSE:ALSN) by 8.8% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 14,497 shares of the auto parts company’s stock after selling 1,400 shares during the quarter. ARP Americas LP’s holdings in Allison Transmission were worth $566,000 at the end of the most recent quarter.

  • [By Ben Levisohn]

    With a neutral sector rating, we are working on evaluating risks to negative calls, and identifying potential value opportunities. Last week we noted more work might be worthwhile on Wabco Holdings (WBC), Terex, Manitowoc (MTW), and Caterpillar, two of those names have rallied for other reasons but the attractive price made the upside/downside skew up. We remain positive (OW) on Allison Transmission Holdings (ALSN) & United Rentals. Our and consensus 2017Allison Transmission Holdings estimates have fallen by 2% vs. ~15% for the group, while the shares are down 10% since launch. We continue to see United Rentals as the best value in our group…

Hot Small Cap Stocks To Buy For 2018: ON Semiconductor Corporation(ON)

Advisors’ Opinion:

  • [By ]

    Though concerns have been raised that the analog and MCU markets are at risk of seeing an inventory correction (they haven’t had a major one in a while), given signs of excessive ordering and stretched lead times, TI and STMicro’s numbers suggest conditions remain good for now. That’s particularly true in industrial and auto markets where trends such as factory automation, ADAS adoption and electric/hybrid car sales are boosting chip demand. Several other analog/MCU firms, including Microchip (MCHP) , ON Semiconductor (ON) , Maxim Integrated (MXIM) and NXP Semiconductors (NXPI) , will be reporting soon.

  • [By Lee Jackson]

    Aggressive accounts may want to look at this smaller cap play. ON Semiconductor Corp. (NASDAQ: ON) is a vendor of analog power management, analog signal conditioning, standard logic integrated circuits and discrete chips into the automotive, communications, computing, consumer, industrial and medical applications. The company is in the midst of a transformation from a seller of commodity discrete chips into higher value added analog integrated circuits, both through organic growth and acquisitions.

Top 10 Value Stocks To Buy Right Now

&l;p&g;&l;img class=&q;dam-image ap size-large wp-image-e1b245db90ee410e96d9a53f05882f61&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/e1b245db90ee410e96d9a53f05882f61/960×0.jpg?fit=scale&q; data-height=&q;640&q; data-width=&q;960&q;&g; AP Photo

Limiting the research to just those stocks listed on the New York Stock Exchange — and which seem to qualify as &q;value&q; stocks based certain qualities inherent in the old school Benjamin Graham-style criteria –here are 4 that look intriguing:

&l;strong&g;Seaspan Corporation&l;/strong&g; is a Hong Kong based shipping company now trading at half its book value and with a price/earnings ratio of only 8.3 — a much, much lower p/e than that of the S&a;amp;P 500. These 2 metrics make it appear to be qualified as a value stock.

&l;img class=&q;size-full wp-image-3116&q; src=&q;http://blogs-images.forbes.com/johnnavin/files/2018/04/ssw-daily-4-21-18-j.jpg?width=960&q; alt=&q;&q; data-height=&q;928&q; data-width=&q;1240&q;&g; Seaspan chart.

Top 10 Value Stocks To Buy Right Now: NxStage Medical, Inc.(NXTM)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Thursday, healthcare shares dipped by 0.51 percent. Meanwhile, top losers in the sector included NxStage Medical, Inc. (NASDAQ: NXTM), down 8 percent, and Valeant Pharmaceuticals Intl Inc (NYSE: VRX), down 9 percent.

Top 10 Value Stocks To Buy Right Now: Globus Maritime Limited(GLBS)

Advisors’ Opinion:

  • [By Lisa Levin] Related NVCN 18 Biggest Mid-Day Losers For Wednesday Legal Overhangs Keep Ladenburg Neutral On Neovasc Despite Positive Tiara Clinical Data Boston Scientific closes Neovasc transaction (Seeking Alpha)
    Related BSX Watch These 10 Huge Call Purchases In Monday Trade Wonderful Wearables Get Their Own ETF Boston Scientific closes Neovasc transaction (Seeking Alpha) Gainers
    Neovasc Inc (US) (NASDAQ: NVCN) rose 17.3 percent to $2.65 in pre-market trading after the company reported the close of its $75 million transaction with Boston Scientific Corporation (NYSE: BSX).
    aTyr Pharma Inc (NASDAQ: LIFE) shares rose 12.3 percent to $4.10 in pre-market trading after the company disclosed 'promising' signals in myopathies with Resolaris in exploratory trials.
    Globus Maritime Ltd (NASDAQ: GLBS) shares rose 10.1 percent to $6.90 in pre-market trading after climbing 5.03 percent on Monday.
    Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares rose 9.9 percent to $3.00 in pre-market trading. Aurinia Pharmaceuticals appointed Lorin Jeffry “Jeff” Randall to its board and Chairman of the Audit Committee.
    Ocean Rig UDW Inc. (NASDAQ: ORIG) shares rose 8.7 percent to $2.89 in pre-market trading after surging 19.82 percent on Monday.
    Full House Resorts, Inc. (NASDAQ: FLL) shares rose 5.1 percent to $2.08 in pre-market trading after declining 1.98 percent on Monday.
    Seadrill Ltd (NYSE: SDRL) rose 5.1 percent to $4.13 in pre-market trading after surging 3.15 percent on Monday.
    Noble Corporation (NYSE: NE) rose 5.1 percent to $7.60 in pre-market trading after declining 5.37 percent on Monday.
    Arbutus Biopharma Corp (NASDAQ: ABUS) rose 5.1 percent to $3.10 in pre-market trading. Arbutus issued additional data from its ARB-1467 Phase II
  • [By William Romov]

    Last Wednesday (Dec. 6), the company received a patent for certain methods of production of its phase 2 antidepressant, AV-101.

    Penny Stock Current Share Price Dec. 4 – Dec. 8 Gain (as of Dec. 8)
    VistaGen Therapeutics Inc. (Nasdaq: VTGN) $1.80 135%
    FXCM Inc. (Nasdaq: GLBR) $1.12 124%
    Neuralstem Inc. (Nasdaq: CUR) $2.00 75.44%
    Ohr Pharmaceuticals Inc. (Nasdaq: OHRP) $1.49 75.29%
    ClearSign Combustion Corp. (Nasdaq: CLIR) $3.50 53.85%
    Astrotech Corp. (Nasdaq: ASTC) $4.21 51.99%
    Burcon NutraScience Corp. (Nasdaq: BUR) $0.72 44%
    LM Funding America Inc. (Nasdaq: LMFA) $3.72 42.53%
    Second Sight Medical Products Inc. (Nasdaq: EYES) $1.75 42.28%
    Globus Maritime Ltd. (Nasdaq: GLBS) $1.47 41.35%

    As a result, its share price shot up from $0.92 to $2.52 on Wednesday. The stock pulled back to $1.80 by the end of the week, for a total gain of 135% for the week.

  • [By Lisa Levin]

    Globus Maritime Ltd (NASDAQ: GLBS) shares shot up 177 percent to $13.67 after gaining 72.73 percent on Tuesday. Globus Maritime is up 175.9 percent since Election Day.

  • [By Wayne Duggan]

    DryShips isn’t the only shipping stock that has skyrocketed this month; the following stocks’ shares are all up between 320 and 720 percent since November 2:

    Diana Containerships Inc (NASDAQ: DCIX). Euroseas Ltd. (NASDAQ: ESEA). Globus Maritime Ltd (NASDAQ: GLBS). Sino-Global Shipping America, Ltd. (NASDAQ: SINO).

    One of the primary reasons for the extreme moves in DryShips and other shipping stocks is a combination of large short positions in the stocks and extremely low share counts. DryShips in particular lowered its share count from around 672 million to only around 1 million via a series of reverse stock-splits throughout the year. The splits were intended to allow the stock to maintain its Nasdaq listing after it had lost more than 98 percent of its value in the first 10 months of 2016.

Top 10 Value Stocks To Buy Right Now: ADDvantage Technologies Group, Inc.(AEY)

Advisors’ Opinion:

  • [By Jim Robertson]

    Today, our Under the Radar Moversnewsletter suggestedshorting small cap cable television and telecommunications equipment stock ADDvantage Technologies Group, Inc (NASDAQ: AEY):

Top 10 Value Stocks To Buy Right Now: Netlist, Inc.(NLST)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Friday, our Elite Opportunity Pronewsletter suggested small cap data/memory solutions stocksNetlist, Inc (NASDAQ: NLST) as a long/bullish position for our short term portfolio:

Top 10 Value Stocks To Buy Right Now: Helios and Matheson Analytics Inc(HMNY)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Helios and Matheson Analytics Inc. (NASDAQ: HMNY) were down 40 percent to $2.29 after pricing public share offering.

    Sears Hometown and Outlet Stores, Inc. (NASDAQ: SHOS) was down, falling around 29 percent to $2.30. Sears Hometown and Outlet Stores reported a Q4 loss of $1.46 per share on revenue of $395.77 million.

  • [By Paul Ausick]

    The subscription service is controlled by Helios & Matheson Analytics Inc. (NASDAQ: HMNY), which owns about 81% of MoviePass stock.

    MoviePass CEO Mitch Lowe commented:

  • [By Lisa Levin] Gainers
    Check-Cap Ltd. (NASDAQ: CHEK) shares rose 78.82 percent to close at $7.26 on Monday.
    GEE Group, Inc. (NYSE: JOB) shares jumped 18 percent to close at $2.36.
    McDermott International, Inc. (NYSE: MDR) climbed 15.7 percent to close at $7.00 after the UK-based offshore oil service company Subsea 7 made an unsolicited bid to buy McDermott for $7 per share. However, the acquisition offer is contingent on McDermot terminating its pending merger with Chicago Bridge & Iron Company.
    Foresight Autonomous Holdings Ltd (NASDAQ: FRSX) gained 17.21 percent to close at $3.61.
    Stars Group Inc. (NASDAQ: TSG) rose 14.16 percent to close at $33.45. Stars Group Inc (NASDAQ: TSG) announced plans to acquire Sky Betting & Gaming for $4.7 billion.
    China Internet Nationwide Financial Services Inc. (NASDAQ: CIFS) shares jumped 12.79 percent to close at $25.58.
    Nautilus, Inc. (NYSE: NLS) shares gained 11.52 percent to close at $15.00. Nautilus is expected to release Q1 results on May 7, 2018. Craig-Hallum initiated coverage on Nautilus with a Buy rating and a $19.00 price target.
    Box, Inc. (NYSE: BOX) rose 10.94 percent to close at $22.91.
    Insmed Incorporated (NASDAQ: INSM) shares rose 10.76 percent to close at $26.05. Credit Suisse upgraded Insmed from Neutral to Outperform.
    NextDecade Corporation (NASDAQ: NEXT) shares rose 10.02 percent to close at $6.48.
    Helios and Matheson Analytics Inc. (NASDAQ: HMNY) shares gained 8.37 percent to close at $2.46 on Monday after falling 10.98 percent on Friday.
    Cambium Learning Group, Inc. (NASDAQ: ABCD) shares gained 7.81 percent to close at $11.11.
    Vectren Corporation (NYSE: VVC) shares rose 7.26 percent to close at $70.31. CenterPoint Energy, Inc. (NYSE: CNP) announced plans to acquire Vectren for $72 per share in cash.
    Tennant Company (NYSE: TNC) rose 6.66 percent to close at $74.45 after the company posted upbeat Q1 results and raised its FY18 earnings outlook.
    Hanesbrands Inc.

Top 10 Value Stocks To Buy Right Now: Yanzhou Coal Mining Company Limited(YZC)

Advisors’ Opinion:

  • [By Lisa Levin]

    Thursday afternoon, energy shares slipped by just 0.1 percent. Meanwhile, top gainers in the sector included Superior Energy Services, Inc. (NYSE: SPN), and Yanzhou Coal Mining Co Ltd (ADR) (NYSE: YZC).

Top 10 Value Stocks To Buy Right Now: Park Hotels & Resorts Inc. (PK)

Advisors’ Opinion:

  • [By Paul Ausick]

    Park Hotels & Resorts Inc. (NYSE: PK) fell about 2.7% Monday to post a new 52-week low of $23.91 after closing at $24.42 on Friday. The 52-week high is $29.93. Volume of more than 4.1million was more than double the daily average. The company announced a secondary offering of nearly 33 million shares along with an additional 4.94 million as an underwriter’s option and a private transaction involving another 15.75 million shares. All shares in the offering are being sold by HNA HLT Holdco I LLC, and none of the proceeds go to Park.

Top 10 Value Stocks To Buy Right Now: World Fuel Services Corporation(INT)

Advisors’ Opinion:

  • [By Lisa Levin]

    World Fuel Services Corporation (NYSE: INT) shares dropped 21 percent to $22.05 following Q1 results.

    Shares of Biglari Holdings Inc. (NYSE: BH) were down 17 percent to $352.05. Washington Prime Group Inc. (NYSE: WPG) will replace Biglari Holdings in the S&P SmallCap 600 on Tuesday, May 1.

Top 10 Value Stocks To Buy Right Now: Ultra Clean Holdings, Inc.(UCTT)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Friday, technology shares fell 3.59 percent. Meanwhile, top losers in the sector included Ultra Clean Holdings Inc (NASDAQ: UCTT), down 5 percent, and Brooks Automation, Inc (NASDAQ: BRKS), down 10 percent.

  • [By Lisa Levin]

    In trading on Monday, technology shares fell 0.65 percent. Meanwhile, top losers in the sector included Ultra Clean Holdings Inc (NASDAQ: UCTT), down 4 percent, and Mitek Systems, Inc. (NASDAQ: MITK), down 7 percent.

  • [By Lisa Levin] Gainers
    Comstock Resources, Inc. (NYSE: CRK) shares shot up 52 percent to $7.235 after the company disclosed a deal with Arkoma Drilling L.P. and Williston Drilling, L.P. to buy oil & gas properties in North Dakota. Comstock announced withdrawal of tender offers for outstanding secured notes.
    MarineMax, Inc. (NYSE: HZO) shares gained 24.2 percent to $21.80 as the company posted upbeat Q2 results and raised its FY18 outlook.
    Mattersight Corporation (NASDAQ: MATR) shares rose 22 percent to $2.625 after the company agreed to be purchased by NICE Ltd.
    Chipotle Mexican Grill, Inc. (NYSE: CMG) jumped 21.3 percent to $411.871 as the company reported stronger-than-expected results for its first quarter on Wednesday.
    Axsome Therapeutics, Inc. (NASDAQ: AXSM) rose 17 percent to $3.10 after the company disclosed a positive outcome of the interim analysis of STRIDE-1 Phase 3 trial of AXS-05 in treatment resistant depression.
    Ultra Clean Holdings, Inc. (NASDAQ: UCTT) rose 15.9 percent to $18.34 following upbeat Q1 earnings.
    PCM, Inc. (NASDAQ: PCMI) gained 15.6 percent to $12.20 following Q1 results.
    O'Reilly Automotive, Inc. (NASDAQ: ORLY) surged 14.4 percent to $260.3901 following upbeat Q1 profit.
    Concord Medical Services Holdings Limited (NYSE: CCM) gained 13.8 percent to $3.70.
    Penn National Gaming, Inc. (NASDAQ: PENN) rose 13.5 percent to $29.815 after reporting strong Q1 results.
    BioTelemetry, Inc. (NASDAQ: BEAT) rose 13.5 percent to $38.30 as the company reported stronger-than-expected earnings for its first quarter.
    Advanced Micro Devices, Inc. (NASDAQ: AMD) shares rose 13.1 percent to $10.985 as the company reported upbeat results for its first quarter.
    SJW Group (NYSE: SJW) shares gained 11.8 percent to $63.59 following Q1 results. California Water Service Group made an offer for SJW.
    Churchill Downs Incorporated (NASDAQ: CHDN) climbed 9.8 percent to $278.40 following Q1 results.
    CYS Investments, Inc. (NYSE: CYS)

Top 10 Value Stocks To Buy Right Now: Resonant Inc.(RESN)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Daré Bioscience, Inc. (NASDAQ: DARE) shares jumped 56.69 percent to close at $1.27 on Wednesday on news that the company entered into worldwide license agreement for Juniper Pharmaceuticals' intravaginal ring technology platform.
    Vicor Corporation (NASDAQ: VICR) rose 26.84 percent to close at $37.10. Vicor posted Q1 earnings of $0.10 per share on sales of $65.2 million.
    AGM Group Holdings Inc. (NASDAQ: AGMH) climbed 25.56 percent to close at $10.61.
    Travelzoo (NASDAQ: TZOO) gained 24.7 percent to close at $9.75 following strong Q1 results.
    Intrepid Potash, Inc. (NYSE: IPI) shares climbed 19.24 percent to close at $4.71.
    China Customer Relations Centers, Inc. (NASDAQ: CCRC) rose 18.73 percent to close at $18.64.
    Genprex, Inc. (NASDAQ: GNPX) climbed 18.28 percent to close at $5.89. Genprex expanded its operations to Cambridge, Mass.
    Scorpio Tankers Inc. (NYSE: STNG) rose 13.92 percent to close at $2.70 following Q1 results.
    Rocky Brands, Inc. (NASDAQ: RCKY) shares surged 13.57 percent to close at $23.85 after reporting Q1 results.
    Resonant Inc. (NASDAQ: RESN) shares rose 12.5 percent to close at $4.14 on Wednesday.
    USANA Health Sciences, Inc. (NYSE: USNA) jumped 11.24 percent to close at $106.85 following Q1 results.
    SUPERVALU Inc. (NYSE: SVU) rose 11.16 percent to close at $16.24 after the company reported Q4 results and agreed to sell and leaseback eight distribution centers for an aggregate purchase price of $483 million.
    K12 Inc. (NYSE: LRN) shares gained 10.74 percent to close at $15.36 following Q3 results.
    Tupperware Brands Corporation (NYSE: TUP) rose 9.15 percent to close at $46.28 as the company posted in-line quarterly earnings.
    Six Flags Entertainment Corporation (NYSE: SIX) shares climbed 8.49 percent to close at $64.18 as the company posted a narrower-than-expected loss for its first quarter.
    Carlisle Companies Incorporated (NYSE: CSL) gained 8.2 percent to close at $107.94 af

Top Stocks To Invest In 2018

&l;p&g;Pretty much since 1986, businesses have been able to deduct 50 percent of business-related entertainment and meal expenses.&a;nbsp; Furthermore, meals provided by an employer to employees on its premises have been fully deductible.&a;nbsp; In addition, qualified transportation fringe benefits, such as work-related parking costs have been deductible to the employer.&a;nbsp; Much of this is expected to change under the Tax Cuts and Jobs Act (the &a;ldquo;Act&a;rdquo;).

&l;img class=&q;dam-image shutterstock size-large wp-image-781744174&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/781744174/960×0.jpg?fit=scale&q; data-height=&q;637&q; data-width=&q;960&q;&g; Shutterstock

The Act eliminates deductions for entertainment, amusement, recreation expenses, and membership dues.&a;nbsp; Though meal expenses associated with operating a business, such as meals during employee travel, remain deductible subject to the fifty percent limitation.&a;nbsp; The Act also disallows deductions for qualified transportation fringe benefits.&a;nbsp; The reasoning behind the elimination of these deductions is that businesses will see their tax rates reduced under the Act, so the elimination or reduction of these deductions are only fair.&a;nbsp; In other words, the elimination of these deductions helped pay for the reduction in the business tax rates.

Top Stocks To Invest In 2018: Cencosud S.A.(CNCO)

Advisors’ Opinion:

  • [By Javier Hasse]

    “Right now, we are the only Latin American company in the retail segment, and the only ones with a real distribution chain assembled, selling in stores like Staples and others,” Caporale explained. “Stratasys, Ltd. (NASDAQ: SSYS)’s MakerBot had a few experiences in retail, but did not do very well: Cencosud SA (NYSE: CNCO)’s Jumbo supermarkets bought three printers [for its Argentina branch] and did not manage to sell any. The thing is, their machine costs about 90,000 Argentine pesos [about $6,000], and our machine goes for 32,000 pesos [about $2100].”

  • [By Jim Robertson]

    Today, our Under the Radar Moversnewsletter suggested shorting mid cap emerging markets retail stock Cencosud SA (NYSE: CNCO):

    There are a couple of things going on here to lead us to a bearish conclusion, but the biggest of these is today’s cross under the 200-day moving average line (green) at $8.46. For a brief while it looked like this long-term moving average line was going to play a support role – as it often does – but today’s second selling effort broke its back. Now that the floor’s out of the way, the selling just got a lot easier.

Top Stocks To Invest In 2018: Sigma Designs, Inc.(SIGM)

Advisors’ Opinion:

  • [By Lisa Levin]

    Gainers

    Pyxis Tankers Inc. (NYSE: PXS) rose 47.48 percent to $$5.56, after the company announced it has entered into a definitive securities purchase agreement with a group of investors, which will result in gross proceeds of $4.8 million.
    Sigma Designs Inc (NASDAQ: SIGM) rose 22.77 percent to $6.88. Silicon Laboratories (NASDAQ: SLAB) announced plans to buy Sigma Designs for $7.05 per share in cash.
    Steadymed Ltd (NASDAQ: STDY) rose 19.35 percent to $3.70, after the company reported that no clinical trials were required for Trevyent and that the FDA had agreed to the pathway for the drug candidate's NDA resubmission.
    Iteris, Inc. (NASDAQ: ITI) rose 15.73 percent to $7.06. Earlier in the week, Zacks Investment Research had upgraded the company from "Sell" to "Hold".
    Science Applications International Corp (NYSE: SAIC) rose 13.71 percent to $85.77 as the company reported better-than-expected earnings for its third quarter.
    Technical Communications Corporation (NASDAQ: TCCO) rose 12.41 percent to $6.07, after having risen sharply in pre-marketing trading.
    Radius Health, Inc. (NASDAQ: RDUS) rose 12.41 percent to $30.81 after the company provided an update on data from the Phase 1 005 clinical study of elacestrant in patients with estrogen receptor positive breast cancer during the 2017 San Antonio Breast Cancer Symposium.
    ForeScout Technologies, Inc. (NASDAQ: FSCT) rose 12.32 percent to $25.80 after the company reported its third quarter financial results.
    Prana Biotechnology Limited (NASDAQ: PRAN) rose 11.36 percent to $3.43, as the company announced a research collaboration with Takeda Pharmaceuticals to study the ability of movement disorders compound, PBT434 to slow or prevent neurodegeneration of the gastrointestinal system.
    Catalyst Biosciences, Inc. (NASDAQ: CBIO) rose 10.49 percent to $7.90 as the company announced the appointment of Arwa Shurrab and Jamie Ellen Siegel in its clinical hemophilia

  • [By Lisa Levin]

    Sigma Designs Inc (NASDAQ: SIGM) shares dropped 30 percent to $5.43. Sigma Designs reported fiscal third-quarter net income of $221,000 on revenue of $62.7 million.

  • [By Paul Ausick]

    Sigma Designs Inc. (NASDAQ: SIGM) dropped about 34% on Wednesday to post a new 52-week low of $5.20 against a 52-week high of $8.60 and a Tuesday close of $7.75. Volume of about 6.2 million was about 25 times the daily average of around 280,000. The company reported so-so earnings on Tuesday and the stock was downgraded and price targets lowered by several analysts.

Top Stocks To Invest In 2018: NxStage Medical, Inc.(NXTM)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Thursday, healthcare shares dipped by 0.51 percent. Meanwhile, top losers in the sector included NxStage Medical, Inc. (NASDAQ: NXTM), down 8 percent, and Valeant Pharmaceuticals Intl Inc (NYSE: VRX), down 9 percent.